Analysts Set Expectations for Gilead Sciences FY2026 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Gilead Sciences in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst C. Gould expects that the biopharmaceutical company will earn $9.39 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $125.00 target price on the stock. The consensus estimate for Gilead Sciences' current full-year earnings is $7.95 per share.

GILD has been the topic of several other reports. Royal Bank of Canada upped their price objective on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research report on Wednesday, February 12th. Bank of America lifted their price objective on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. The Goldman Sachs Group increased their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Finally, Oppenheimer dropped their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Stock Down 2.6%

NASDAQ:GILD traded down $2.91 during trading hours on Tuesday, reaching $110.09. 8,870,755 shares of the company traded hands, compared to its average volume of 7,749,500. Gilead Sciences has a 1 year low of $62.69 and a 1 year high of $119.96. The stock has a market capitalization of $136.94 billion, a P/E ratio of 297.54, a P/E/G ratio of 0.71 and a beta of 0.29. The business's 50-day moving average price is $105.41 and its two-hundred day moving average price is $101.80. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business's quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the company earned ($1.32) EPS.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.87%. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the transaction, the chief financial officer now owns 165,674 shares of the company's stock, valued at approximately $16,537,578.68. The trade was a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the sale, the insider now directly owns 121,152 shares in the company, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,000 shares of company stock valued at $4,630,310 in the last ninety days. Corporate insiders own 0.27% of the company's stock.

Institutional Trading of Gilead Sciences

Several large investors have recently added to or reduced their stakes in the stock. Bridgewater Associates LP increased its position in Gilead Sciences by 122.7% during the fourth quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock worth $42,577,000 after purchasing an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV increased its holdings in shares of Gilead Sciences by 5.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after buying an additional 14,009 shares during the last quarter. Ontario Teachers Pension Plan Board raised its position in shares of Gilead Sciences by 54.6% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock valued at $3,422,000 after buying an additional 13,086 shares during the period. Mufg Securities Americas Inc. acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $1,699,000. Finally, Convergence Investment Partners LLC lifted its holdings in Gilead Sciences by 15.8% in the fourth quarter. Convergence Investment Partners LLC now owns 68,447 shares of the biopharmaceutical company's stock valued at $6,322,000 after acquiring an additional 9,330 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.